Press Release and disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Natco Pharma Limited Regd. Off.: ‘NATCO HOUSE’, Road No.- 2, Banjara Hills, Hyderabad, Telangana, India- 500 034 Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in 28th September, 2026 Corporate Relationship Department The Manager - Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400001 Bandra (E), Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref: Earlier intimation dated 25th August, 2026 regarding the investment in eGenesis, Inc. With reference to the above cited subject, NATCO Pharma Limited ("NATCO") has decided to increase its investment in eGenesis, Inc. from the previously disclosed amount of US$14.00 million to US$16.70 million through its wholly owned subsidiaries. In addition, there has been a change in the subsidiaries participating in the investment. The updated details of the investment and the subsidiaries involved are set out in the Annexure. Please find enclosed herewith the Disclosure and Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the investment in eGenesis, Inc. This is for your information and records. Thanking you, Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl: As above Natco Pharma Limited Regd. Off. Press Release NATCO Pharma Ltd Natco House Road No.2, Banjara Hills Hyderabad-500 034, India Updat e to disclosure dated August 25, 2026 under SEBI (LODR) Regulations, 2015 This is in furtherance of the disclosure made by NATCO Pharma Limited on August 25, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“LODR”). NATCO Pharma Limited ("NATCO") has decided to increase its investment in eGenesis, Inc. from the previously disclosed amount of US$14.00 million to US$16.70 million through its wholly owned subsidiaries. In addition, there has been a change in the subsidiaries participating in the investment. The updated details of the investment and the subsidiaries involved are set out in the accompanying disclosure submitted under the LODR Regulations. Earlier, in 2024, NATCO had invested US$8.00 million in eGenesis through NATCO Pharma (Canada) Inc. Upon completion of the proposed investment, NATCO's total investment in eGenesis will increase to US$24.70 million. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure and heart transplant. In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway. It was followed by porcine kidney transplants in additional two patients. The outcomes have been exceptionally positive. About NATCO Pharma Limited NATCO Pharma Limited is a vertically integrated pharmaceutical company headquartered in Hyderabad, India. With a strong focus on research and development, NATCO Pharma is dedicated to delivering high-quality and affordable medicines to patients worldwide. About eGenesis, Inc. eGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases. For further information or queries please contact: Rajeev Menon – Manager, Investor Relations Email: r.menon@natcopharma.co.in Tel: 040-23547532 / Ext – 323 Follow us on: X (formerly Twitter): https://twitter.com/pharma_natco LinkedIn: https://www.linkedin.com/company/natcopharma Natco Pharma Limited Regd. Off.: ‘NATCO HOUSE’, Road No.- 2, Banjara Hills, Hyderabad, Telangana, India- 500 034 Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in Annexure Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201a5 The below disclosure is being made in further to our disclosure dated August 25, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Investment of US$ 16.70 million in eGenesis, Inc., comprising US$ 13.70 million by NATCO Pharma (Canada) Inc. and US$ 3 million by NATCO Pharma USA LLC through convertible promissory notes Sl. Particulars Details of Investment A Name of the target entity, details in 1) Name of the target entity brief such as size, turnover etc. eGenesis, Inc. 2) Details in brief such as size, turnover etc. It is an R&D company engaged in using its multiplex gene editing and genome engineering platform to research and develop porcine solid organ donors for use in human transplantation for patients with serious diseases causing organ failure. B Whether the acquisition would fall No within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” C Industry to which the entity being Biotechnology acquired belongs D Objects and effects of acquisition Investing in new-age therapeutic programmes (including but not limited to, disclosure addressing critical unmet medical needs of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) E Brief details of any governmental or - regulatory approvals required for the acquisition F Indicative time period for completion October 31, 2026 of the acquisition; G Nature of consideration - whether cash Cash consideration for subscribing to convertible consideration or share swap and details promissory notes of the same H Cost of acquisition or the price at which US$ 13.70 million by NATCO Pharma (Canada) Inc. the shares are acquired and US$ 3 million by NATCO Pharma USA LLC Natco Pharma Limited Regd. Off.: ‘NATCO HOUSE’, Road No.- 2, Banjara Hills, Hyderabad, Telangana, India- 500 034 Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in Sl. Particulars Details of Investment I Percentage of shareholding / control NATCO Pharma (Canada) Inc. is purchasing a acquired and / or number of shares Convertible Promissory Note with a principal acquired amount of US$ 13.70 million with an interest rate of 8% compounded annually and NATCO Pharma USA LLC is purchasing a Convertible Promissory Note with a principal amount of US$ 3 million with an interest rate of 8% compounded annually. At the time of completion of this acquisition, no additional shares are being acquired. J brief background about the entity 1. Brief background: acquired in terms of products/line of business acquired, date of eGenesis, Inc. is a clinical stage company incorporation, history of last 3 years engaged in using its multiplex gene editing turnover, country in which the and genome engineering platform to address acquired entity has presence and any numerous mechanisms of human rejection of other significant information (in brief) non-human organs. The company is currently in clinical trials for porcine kidney transplantation in humans and porcine liver perfusion with a goal of addressing the fundamental limitation of human donor availability for patients with serious diseases resulting in acute and chronic [Showing first 8,000 characters — download PDF for full document]